Navigation Links
Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean

WILMINGTON, N.C., Nov. 27 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced the appointment of Jose Luis Viramontes, M.D., as associate director of clinical operations, to lead the company's delivery of drug development services in Mexico, Central America and the Caribbean. Based in Mexico City, Dr. Viramontes will provide overall management of PPD clinical services in the region.

"Dr. Viramontes brings a solid understanding of the pharmaceutical industry in Mexico, extensive clinical research experience and strong leadership skills," said Wendy Buckland, senior executive director of clinical operations for Latin America. "He will play a lead role in expanding our global presence in Latin America, and we are pleased to welcome him to PPD."

A physician, Dr. Viramontes joins PPD from Merck Sharp & Dohme Mexico where he spent 14 years in roles with increasing responsibilities. Most recently, he served as clinical research associate director. In this role, he oversaw clinical trials, including site validation and selection; identified and developed clinical research preferred partners; ensured consistency of process and protocol implementation; and coordinated clinical research training. His earlier roles with Merck included market expansion manager, medical director, product manager and cardiovascular medical manager.

Dr. Viramontes earned a medical degree from the Universidad Nacional Autonoma de Mexico and completed a specialty in respiratory medicine at the General Hospital of Mexico. He also holds a master in sciences certificate in medical sciences and clinical research. He earned a certificate in clinical epidemiology and health economics from McMaster University in Ontario, Canada. In addition, Dr. Viramontes has a post-graduate certificate in marketing and is knowledgeable of Six Sigma methodology.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the above-named employee's performance and value to PPD contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; competition within the outsourcing industry; continued success in sales growth; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.



Sue Ann Pentecost

+919 456 5890


Steve Smith

+910 558 7585

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
Breaking Biology News(10 mins):